Emergent BioSolutions Inc. (EBS)
| Previous close | 9.20 |
| Open | 9.05 |
| Bid | 9.45 x 800 |
| Ask | 9.47 x 800 |
| Day's range | 9.01 - 9.86 |
| 52-week range | 1.42 - 15.10 |
| Volume | |
| Avg. volume | 3,072,112 |
| Market cap | 499.967M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.22 |
| Earnings date | 06 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
GlobeNewswireEmergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
GAITHERSBURG, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it entered into a new credit agreement on September 30, 2024 providing for an asset-based revolving loan facility (ABL) with the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent. The credit agreement provides for revolving loan commitments in an aggregate principal amount up to $100 million (availability is based on a borrowing base set forth t
Simply Wall St.High Growth Tech Stocks To Watch This October 2024
Over the last 7 days, the market has remained flat, but over the past 12 months, it has risen by an impressive 33%, with earnings forecast to grow by 15% annually. In such a dynamic environment, identifying high growth tech stocks that can capitalize on these trends becomes crucial for investors looking to enhance their portfolios.
- GlobeNewswire
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment courses of TEMBEXA® (brincidofovir) to sustain the U.S. government’s national preparedness posture against human smallpox. TEMBEXA® is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The order is valued at $67.4 million and executes procuremen